News coverage about BioTelemetry (NASDAQ:BEAT) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. BioTelemetry earned a coverage optimism score of 0.23 on Accern’s scale. Accern also assigned news stories about the medical research company an impact score of 46.5315014911198 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the media headlines that may have impacted Accern Sentiment’s analysis:
- BidaskClub Upgrades BioTelemetry (BEAT) to “Buy” (americanbankingnews.com)
- BioTelemetry, Inc. (BEAT) : Stock in the Analysts Spotlight – Wall Street Morning (wallstreetmorning.com)
- Lookout for Simple Moving Averages – BioTelemetry, Inc. (NASDAQ:BEAT) – Stocks Pen (stockspen.com)
- BioTelemetry, Inc. (BEAT) Given Consensus Recommendation of “Hold” by Analysts (americanbankingnews.com)
- BioTelemetry, Inc. to Release Fourth Quarter 2017 Earnings Results on February 22, 2018 (finance.yahoo.com)
Several analysts recently weighed in on the stock. BidaskClub upgraded shares of BioTelemetry from a “hold” rating to a “buy” rating in a report on Wednesday, February 14th. Zacks Investment Research cut shares of BioTelemetry from a “hold” rating to a “sell” rating in a report on Thursday, February 8th. Raymond James Financial assumed coverage on shares of BioTelemetry in a report on Thursday, October 26th. They issued an “outperform” rating and a $37.00 price target on the stock. Dougherty & Co reiterated a “buy” rating and issued a $40.00 price target on shares of BioTelemetry in a report on Wednesday, November 8th. Finally, SunTrust Banks assumed coverage on shares of BioTelemetry in a report on Monday, October 23rd. They issued a “buy” rating and a $41.00 price target on the stock. Two analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $42.86.
ILLEGAL ACTIVITY WARNING: “BioTelemetry (BEAT) Getting Somewhat Positive News Coverage, Analysis Shows” was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://stocknewstimes.com/2018/02/20/biotelemetry-beat-getting-somewhat-positive-news-coverage-analysis-shows.html.
BioTelemetry Company Profile
BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.